On Josh Lehrer’s first day as CEO of Marea Therapeutics in October 2023, he found out the biotech’s second pipeline drug hadn’t lived up to the startup’s expectations in a monkey study.
The Bay Area …
Read More from Endpoints News
Marea takes drug for acromegaly to Phase 2
